Market Overview

UPDATE: Stifel Nicolaus Raises PT to $85 on Gilead Sciences on HCV Data

Related GILD
Early Global News: Ebola In Liberia, Boeing To Roll Out 737 MAX Next Month, Google Testing SMS Alerts
Gilead's Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia
Strong Drug Development Benefits Cambrex (Investor's Business Daily)

Stifel Nicolaus maintained its Buy rating on Gilead Sciences (NASDAQ: GILD) and increased its price target from $80 to $85.

Stifel Nicolaus commented, "Twelve week sofosbuvir plus BMY's NS5a daclatasvir treatment achieved an impressive SVR4 of 98% in treatment naïve genotype 1 patients, and the same combo with ribavirin achieved a 95% SVR4. … On the Abbott investor call held last night, ABT management indicated that they expect data from its six-trial registrational program in 2013 with market launch in 2015."

Gilead Sciences closed at $73.93 on Monday.

Latest Ratings for GILD

Nov 2015Piper JaffrayUpgradesNeutralOverweight
Oct 2015OppenheimerMaintainsOutperform
Oct 2015JefferiesMaintainsHold

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (GILD)

Get Benzinga's Newsletters